One study details a decline of T-helper cell reactivity against CSPG4 in melanoma patients compared with healthy subjects, suggesting that there may be potential CSPG4-specific protection against melanoma cells in non-malignant states [52]. This evidence concerns the gene CSPG4 and melanoma.